Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Handheld Lab to Enable Faster, Cheaper Point-of-Need Bacterial Infection Identification

By LabMedica International staff writers
Posted on 30 Nov 2022
Print article
Image: Portable, handheld reader, with cloud-based ML algorithms to identify bacterial species within five minutes (Photo courtesy of Nostics)
Image: Portable, handheld reader, with cloud-based ML algorithms to identify bacterial species within five minutes (Photo courtesy of Nostics)

Antimicrobial resistance (AMR) is the unresponsiveness of bacteria to a certain antibiotic due to mutations or resistance genes the species has gained. This is a natural process, however, with the copious amounts of antibiotics that are used, this process is highly accelerated and becomes a danger to our healthcare system. For most people, treatment for bacterial infections is based merely on symptoms, which increases the chance of misdiagnosis and prolonged disease course. Now, instant, accessible, reliable testing for viruses and bacteria will be soon made possible by the world’s smallest portable bacteria identification lab that uses cloud-based, machine learning algorithms to identify bacterial species in five minutes, without the need for expert users or expensive lab infrastructure.

Nostics B.V. (Amsterdam, The Netherlands) is taking spectroscopy where it has never been before: bacterial identification. By combining spectroscopy with nanotechnology and advanced AI classification, the company will soon launch a novel diagnostic tool for point-of-care (PoC) bacterial infection identification. The new digital diagnostics platform from Nostics can provide fast and accurate diagnostics for bacterial infections without the need for costly labs.

The Nostics PoC solution can fit in a backpack, making diagnostics accessible which is the key to combating AMR. By using a handheld device, Raman spectroscopy, cutting-edge nanosurfaces and advanced AI algorithms, the platform has the potential to change the lives of people in places without access to bacterial diagnostics and accelerate this access in countries with more developed healthcare facilities.

Related Links:
Nostics B.V.

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.